You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 17, 2024

Details for Patent: 5,962,219


✉ Email this page to a colleague

« Back to Dashboard


Title: Systematic evolution of ligands by exponential enrichment: chemi-selex
Abstract:This application provides methods for identifying nucleic acid ligands capable of covalently interacting with targets of interest. The nucleic acids can be associated with various functional units. The method also allows for the identification of nucleic acids that have facilitating activities as measured by their ability to facilitate formation of a covalent bond between the nucleic acid, including its associated functional unit, and its target.
Inventor(s): Gold; Larry (Boulder, CO), Eaton; Bruce (Boulder, CO), Smith; Drew (Boulder, CO), Wecker; Matthew (Boulder, CO), Jensen; Kirk (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Jun 05, 1995
Application Number:08/460,888
Claims:1. A method for identifying nucleic acids having a facilitating activity from a candidate mixture comprised of nucleic acids wherein each nucleic acid has at least one nucleic acid region and at least one chemically reactive functional unit which binds covalently with a target, said method comprising:

a) contacting the candidate mixture with said target, wherein nucleic acids having a facilitating activity, as indicated by a covalent bond being formed between said target and said chemically reactive functional unit of said nucleic acid, may be partitioned from the remainder of the candidate mixture; and

b) partitioning the nucleic acids having a facilitating activity from the remainder of the candidate mixture, whereby nucleic acids having a facilitating activity are identified.

2. The method of claim 1 wherein after step b), the nucleic acids having a facilitating activity are amplified and steps a) and b) are repeated.

3. The method of claim 1 wherein said chemically reactive functional unit is selected from the group consisting of photoreactive groups, active site directed compounds and peptides.

4. The method of claim 1 wherein the target is modified to include a chemical moiety that reacts with the chemically reactive functional unit of the nucleic acid.

5. The method of claim 1 wherein said nucleic acid comprises a fixed region and a randomized region.

6. The method of claim 5 wherein said at least one chemically reactive functional unit is attached to an oligonucleotide hybridized to said fixed region.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.